September 26, Chuan墓眼科-B (06622.HK) announced that TAB014 (one of the company's core candidate drugs) has completed the last visit of the last patient in the phase III clinical trial for the treatment of wet (neovascular) age-related macular degeneration ("wAMD") on September 20, 2024.

According to the disclosure, the phase III clinical trial of TAB014 is a randomized, double-blind, and non-inferiority study. The main objective of the study is to evaluate the baseline value change in best-corrected visual acuity (BCVA) at week 52 for the group receiving TAB014 treatment compared to the group receiving Lucentis treatment. The study involves approximately 57 centers, with a total of 488 patients enrolled, led by Professor Chen Youxin of Peking Union Medical College Hospital as the principal investigator.